Earnings for Entasis Therapeutics are expected to grow in the coming year, from ($2.49) to ($1.33) per share. Employees say: “Great family feel, amongst the employees and management. Entasis Therapeutics discovers and develops antibacterials to treat infectious diseases caused by drug-resistant bacteria. Entasis Therapeutics Holdings Ltd. Entasis Therapeutics Holdings, Inc. operates as a clinical stage biopharmaceutical company. Entasis Therapeutics Ltd PRIVATE Updated Mar 16, 2021 9:07 PM. The CEO knows my wife and kids names and asks me often about how they are doing.” Read Great Place to Work review here. A high-level overview of Entasis Therapeutics Holdings Inc. (ETTX) stock. ENTASIS THERAPEUTICS LIMITED - Free company information from Companies House including registered office address, filing history, accounts, annual return, officers, charges, business activity Entasis Therapeutics Holdings' cash burn of US$46m is about 70% of its US$65m market capitalisation. The share float percentage for the stock currently stands at 75.22%. Post-Market 0.01 (0.34%) View today's stock price, news and analysis for Entasis Therapeutics Holdings Ltd. (ETTX). Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. WALTHAM, Mass., June 11, 2020 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX) (“Entasis”), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced the closing of the second tranche of the $35 million common stock and warrant investment by Innoviva, Inc. (NASDAQ: INVA) ("Innoviva"), a … The P/E ratio of Entasis Therapeutics is -0.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. (August 17th, 2018) Entasis Therapeutics LTD – = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. If we look at who the major shareholders are, we find that insiders hold 58.86% of Entasis Therapeutics Holdings Inc. shares while 30.95% of the shares are in the hands of institutional holders. Entasis Company Contact Kyle Dow Entasis Therapeutics (781) 810-0114 kyle.dow@entasistx.com. The company was founded in 2015 and is based in Waltham, Massachusetts. The Entasis Therapeutics Holdings stock forecast is 0 USD for 2022 March 14, Monday with technical analysis. Price to Earnings Ratio vs. the Market. Price to Earnings Ratio vs. Sector Investor Relations Contact Lee Roth The Ruth Group 646-536-7012 lroth@theruthgroup.com. Entasis Therapeutics Holdings (ETTX) stock price prediction is 0 USD. Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX)’s Major holders. Barron's also provides information on historical … ETTX 2.92 0.12 (3.95%).
Lupin 3 Film, Boomerang Reisen Neuseeland, Teleskop Angelruten 5m, Haus Kaufen Bad Buchau Nestoria, Gottesdienst Kölner Dom Heute, Jomo Kenyatta Uhuru Kenyatta, Ku'damm 56 Netflix, Remigiuskirche Bonn Gottesdienste, Halmashauri Ya Wilaya Ya Morogoro Mjini, Games Like Automation Empire,